Jeffrey Albores, MD
Pulmonary Disease · Tacoma, WANPI 1497917405
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 429 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,946 and has fallen 95.7% since, to $83 in 2025.
Across 429 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$1K
- GSK$1K
- AstraZeneca$965
- United Therapeutics Corporation$688
- Boehringer Ingelheim$685
- Insmed, Inc.$648
- plus $3K from 26 others
What the payments were for
- Food & beverage$7,91097%
- Education$2243%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 71 | $1,345 |
| GSK | 85 | $1,255 |
| AstraZeneca(2 entities) | 54 | $965 |
| United Therapeutics Corporation | 32 | $688 |
| Boehringer Ingelheim | 38 | $685 |
| Insmed, Inc. | 37 | $648 |
| Gilead | 21 | $505 |
| Sanofi | 20 | $456 |
| Mylan Specialty L.p. | 12 | $218 |
| Merck | 7 | $155 |
| Genentech USA, Inc. | 8 | $124 |
| Vifor Pharma, Inc. | 1 | $107 |
| Bayer | 4 | $98 |
| Sanofi-aventis U.S. LLC | 1 | $97 |
| Grifols USA, LLC | 5 | $95 |
| Regeneron Healthcare Solutions, Inc. | 5 | $93 |
| Mallinckrodt Enterprises LLC | 2 | $89 |
| Electromed, Inc. | 5 | $79 |
| Baxter Healthcare | 2 | $77 |
| Advanced Respiratory, Inc | 3 | $55 |
| Amgen | 3 | $55 |
| Fisher & Paykel Healthcare Inc | 2 | $46 |
| Philips North America LLC | 2 | $40 |
| Portola Pharmaceuticals, LLC | 1 | $31 |
| Shire North American Group Inc | 1 | $22 |
| Novartis | 1 | $20 |
| Circassia Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
| Olympus America Inc. | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,135 in reported general payments places this provider in the 85th percentile of 275 pulmonary disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 92 | $1,149,936 |
| UptraviSelexipag | 42 | $962,525 |
| Orenitram ErTreprostinil Diolamine | 12 | $295,944 |
| OfevNintedanib Esylate | 24 | $243,393 |
| Dupixent PenDupilumab | 53 | $198,870 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 215 | $171,358 |
| Ambrisentan | 20 | $71,081 |
| Tadalafil | 98 | $67,185 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 39 | $32,686 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $31,258 |
| Breo ElliptaFluticasone/Vilanterol | 60 | $28,006 |
| SymbicortBudesonide/Formoterol Fumarate | 69 | $21,527 |
| Advair HfaFluticasone Propion/Salmeterol | 40 | $20,054 |
| Incruse ElliptaUmeclidinium Bromide | 45 | $16,769 |
| Spiriva RespimatTiotropium Bromide | 16 | $14,312 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $1,345 | $2,112,461134 claims |
| Boehringer IngelheimOfev, Spiriva Respimat | $685 | $257,70540 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,255 | $248,819359 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $965 | $52,78699 claims |
| MerckDulera | $155 | $7,70617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 275 pulmonary disease providers in Washington.
Other pulmonary disease in Tacoma
- Babith MankidyTacoma$6K
- Joseph Rey Dago-OcTacoma$5K
- Steven BennettTacoma$4K
- Rajesh KandasamyTacoma$4K
- Vincent MysliwiecTacoma$3K
- Jed GordenSeattle$236K
- Dominique PepperOlympia$212K
- Jiten PatelSpokane$200K
- Oneil BainsSeattle$156K
- Ganesh RaghuSeattle$147K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.